In a significant development within the pharmaceutical industry, UK-based Cycle Pharmaceuticals has offered to acquire Nasdaq-listed Vanda Pharmaceuticals in an all-cash transaction valued at $466 million. Under this proposal, Cycle Pharmaceuticals plans to purchase shares of Vanda Pharmaceuticals at $8 per share, representing a substantial premium over recent closing prices. Financial Details and Premiums Offered […]
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has officially declined the latest acquisition proposal from Future Pak, LLC (FP), citing substantial undervaluation and significant risk. The offer, ranging from $7.25 to $7.75 per share in cash, coupled with certain Contingent Value Rights (CVRs), was unanimously rejected by Vanda’s Board of Directors after thorough consultations with independent financial […]
Vanda Pharmaceuticals has secured orphan drug designation for VPO-227 from the US Food and Drug Administration (FDA) for the treatment of cholera. According to the Nasdaq-listed biopharma company, cholera continues to be a significant public health challenge and recognized unmet medical need in spite of public health efforts over many years. Commenting on VPO-227 FDA […]